Back to Anacor Homepage Developing Drug Candidates Through Boron Chemistry
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
Investors overview.gif
Investor Relations Contact:
ir@anacor.com
Phone: 650-543-7575

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Anacor Pharmaceuticals, Inc.'s financial performance into perspective.

View all »Recent Releases

Jan 8, 2016
Anacor Pharmaceuticals to Present Data From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis at Upcoming Medical Conference

Jan 7, 2016
Anacor Pharmaceuticals Submits New Drug Application to the FDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis

View all »Events & Presentations

Nov 18, 2015 at 8:40 AM UK
Jefferies Autumn 2015 Global Healthcare Conference

Nov 3, 2015 at 8:00 AM ET
Anacor Third Quarter 2015 Financial Results Conference Call

Sep 16, 2015 at 4:15 PM ET
Morgan Stanley Global Healthcare Conference

Receive Email Alerts

Sign up to receive e-mail alerts whenever Anacor posts new information to the site.



(ANAC): NASDAQ
Price: 70.95 Change: +2.38
High: 72.00 %Change: 3.471%
Low: 67.65 Volume: 865,184